{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:13:37Z","timestamp":1790820817497,"version":"4.1.0"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Kyowa Kirin International"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s12325-018-0658-4","type":"journal-article","created":{"date-parts":[[2018,2,6]],"date-time":"2018-02-06T11:38:55Z","timestamp":1517917135000},"page":"135-152","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":81,"title":["A Review of New Findings in Adult T-cell Leukemia\u2013Lymphoma: A Focus on Current and Emerging Treatment Strategies"],"prefix":"10.1007","volume":"35","author":[{"given":"Olivier","family":"Hermine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensei","family":"Tobinai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,6]]},"reference":[{"key":"658_CR1","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/294268a0","volume":"294","author":"BJ Poiesz","year":"1981","unstructured":"Poiesz BJ, Ruscetti FW, Reitz MS, Kalyanaraman VS, Gallo RC. Isolation of a new type C retrovirus (HTLV) in primary uncultured cells of a patient with Sezary T-cell leukaemia. Nature. 1981;294:268\u201371.","journal-title":"Nature"},{"key":"658_CR2","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1073\/pnas.79.6.2031","volume":"79","author":"M Yoshida","year":"1982","unstructured":"Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci USA. 1982;79:2031\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"658_CR3","first-page":"2076","volume-title":"Abeloff\u2019s clinical oncology","author":"K Tsukasaki","year":"2013","unstructured":"Tsukasaki K, Watanabe T, Tobinai K. Adult T-cell leukemia\u2013lymphoma. In: Niederhuber JE, Armitage JO, Doroshow JH, et al., editors. Abeloff\u2019s clinical oncology. 5th ed. Philadelphia: Elsevier Saunders; 2013. p. 2076\u201392.","edition":"5"},{"key":"658_CR4","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124\u201330.","journal-title":"J Clin Oncol"},{"key":"658_CR5","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s11912-013-0332-6","volume":"15","author":"A Marcais","year":"2013","unstructured":"Marcais A, Suarez F, Sibon D, Frenzel L, Hermine O, Bazarbachi A. Therapeutic options for adult T-cell leukemia\/lymphoma. Curr Oncol Rep. 2013;15:457\u201364.","journal-title":"Curr Oncol Rep"},{"key":"658_CR6","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/ijc.2910310404","volume":"31","author":"PD Markham","year":"1983","unstructured":"Markham PD, Salahuddin SZ, Kalyanaraman VS, Popovic M, Sarin P, Gallo RC. Infection and transformation of fresh human umbilical cord blood cells by multiple sources of human T-cell leukemia\u2013lymphoma virus (HTLV). Int J Cancer. 1983;31:413\u201320.","journal-title":"Int J Cancer"},{"key":"658_CR7","doi-asserted-by":"publisher","first-page":"5217","DOI":"10.1158\/1078-0432.CCR-14-0572","volume":"20","author":"K Tsukasaki","year":"2014","unstructured":"Tsukasaki K, Tobinai K. Human T-cell lymphotropic virus type I-associated adult T-cell leukemia\u2013lymphoma: new directions in clinical research. Clin Cancer Res. 2014;20:5217\u201325.","journal-title":"Clin Cancer Res"},{"key":"658_CR8","doi-asserted-by":"publisher","first-page":"282","DOI":"10.5858\/arpa.2012-0379-RS","volume":"138","author":"S Qayyum","year":"2014","unstructured":"Qayyum S, Choi JK. Adult T-cell leukemia\/lymphoma. Arch Pathol Lab Med. 2014;138:282\u20136.","journal-title":"Arch Pathol Lab Med"},{"key":"658_CR9","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3389\/fmicb.2012.00388","volume":"3","author":"A Gessain","year":"2012","unstructured":"Gessain A, Cassar O. Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol. 2012;3:388.","journal-title":"Front Microbiol"},{"key":"658_CR10","doi-asserted-by":"publisher","first-page":"322","DOI":"10.3389\/fmicb.2012.00322","volume":"3","author":"M Iwanaga","year":"2012","unstructured":"Iwanaga M, Watanabe T, Yamaguchi K. Adult T-cell leukemia: a review of epidemiological evidence. Front Microbiol. 2012;3:322.","journal-title":"Front Microbiol"},{"key":"658_CR11","doi-asserted-by":"publisher","first-page":"6058","DOI":"10.1038\/sj.onc.1208968","volume":"24","author":"FA Proietti","year":"2005","unstructured":"Proietti FA, Carneiro-Proietti ABF, Catalan-Soares BC, Murphy EL. Global epidemiology of HTLV-I infection and associated diseases. Oncogene. 2005;24:6058\u201368.","journal-title":"Oncogene"},{"key":"658_CR12","doi-asserted-by":"publisher","first-page":"e517","DOI":"10.1016\/S1470-2045(14)70202-5","volume":"15","author":"K Ishitsuka","year":"2014","unstructured":"Ishitsuka K, Tamura K. Human T-cell leukaemia virus type I and adult T-cell leukaemia\u2013lymphoma. Lancet Oncol. 2014;15:e517\u201326.","journal-title":"Lancet Oncol"},{"key":"658_CR13","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1086\/315088","volume":"180","author":"A Manns","year":"1999","unstructured":"Manns A, Miley WJ, Wilks RJ, et al. Quantitative proviral DNA and antibody levels in the natural history of HTLV-I infection. J Infect Dis. 1999;180:1487\u201393.","journal-title":"J Infect Dis"},{"key":"658_CR14","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3324\/haematol.2012.069476","volume":"98","author":"A Hodson","year":"2013","unstructured":"Hodson A, Laydon DJ, Bain BJ, Fields PA, Taylor GP. Pre-morbid human T-lymphotropic virus type I proviral load, rather than percentage of abnormal lymphocytes, is associated with an increased risk of aggressive adult T-cell leukemia\/lymphoma. Haematologica. 2013;98:385\u20138.","journal-title":"Haematologica"},{"key":"658_CR15","doi-asserted-by":"publisher","first-page":"4795","DOI":"10.1182\/blood-2012-07-440073","volume":"120","author":"JA Laurini","year":"2012","unstructured":"Laurini JA, Perry AM, Boilesen E, et al. Classification of non-Hodgkin lymphoma in Central and South America: a review of 1028 cases. Blood. 2012;120:4795\u2013801.","journal-title":"Blood"},{"key":"658_CR16","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1128\/CMR.00063-09","volume":"23","author":"DU Goncalves","year":"2010","unstructured":"Goncalves DU, Proietti FA, Ribas JG, et al. Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases. Clin Microbiol Rev. 2010;23:577\u201389.","journal-title":"Clin Microbiol Rev"},{"key":"658_CR17","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1182\/blood-2011-03-345702","volume":"118","author":"A Bazarbachi","year":"2011","unstructured":"Bazarbachi A, Suarez F, Fields P, Hermine O. How I treat adult T-cell leukemia\/lymphoma. Blood. 2011;118:1736\u201345.","journal-title":"Blood"},{"key":"658_CR18","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/rmv.1980030304","volume":"3","author":"JE Kaplan","year":"1993","unstructured":"Kaplan JE, Khabbaz RF. The epidemiology of human T-lymphotropic virus types I and II. Rev Med Virol. 1993;3:137\u201348.","journal-title":"Rev Med Virol"},{"key":"658_CR19","doi-asserted-by":"publisher","first-page":"3438","DOI":"10.1002\/cncr.25147","volume":"116","author":"AA Phillips","year":"2010","unstructured":"Phillips AA, Shapira I, Willim RD, et al. A critical analysis of prognostic factors in North American patients with human T-cell lymphotropic virus type-1-associated adult T-cell leukemia\/lymphoma: a multicenter clinicopathologic experience and new prognostic score. Cancer. 2010;116:3438\u201346.","journal-title":"Cancer"},{"key":"658_CR20","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1086\/424598","volume":"190","author":"M Hisada","year":"2004","unstructured":"Hisada M, Stuver SO, Okayama A, et al. Persistent paradox of natural history of human T lymphotropic virus type I: parallel analyses of Japanese and Jamaican carriers. J Infect Dis. 2004;190:1605\u20139.","journal-title":"J Infect Dis"},{"key":"658_CR21","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/(SICI)1097-0215(19990301)80:5<662::AID-IJC5>3.0.CO;2-I","volume":"80","author":"PH Levine","year":"1999","unstructured":"Levine PH, Dosik H, Joseph EM, et al. A study of adult T-cell leukemia\/lymphoma incidence in central Brooklyn. Int J Cancer. 1999;80:662\u20136.","journal-title":"Int J Cancer"},{"key":"658_CR22","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1200\/JCO.2008.18.2428","volume":"27","author":"K Tsukasaki","year":"2009","unstructured":"Tsukasaki K, Hermine O, Bazarbachi A, et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia\u2013lymphoma: a proposal from an international consensus meeting. J Clin Oncol. 2009;27:453\u20139.","journal-title":"J Clin Oncol"},{"key":"658_CR23","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1517\/14656566.2011.571207","volume":"12","author":"CA Dasanu","year":"2011","unstructured":"Dasanu CA. Newer developments in adult T-cell leukemia\/lymphoma therapeutics. Expert Opin Pharmacother. 2011;12:1709\u201317.","journal-title":"Expert Opin Pharmacother"},{"key":"658_CR24","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/j.1365-2141.1991.tb08051.x","volume":"79","author":"M Shimoyama","year":"1991","unstructured":"Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984\u20131987). Br J Haematol. 1991;79:428\u201337.","journal-title":"Br J Haematol"},{"key":"658_CR25","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1182\/blood-2015-03-632489","volume":"126","author":"H Katsuya","year":"2015","unstructured":"Katsuya H, Ishitsuka K, Utsunomiya A, et al. Treatment and survival among 1594 patients with ATL diagnosed in the 2000s: a report from the ATL-PI project performed in Japan. Blood. 2015;126:2570\u20137.","journal-title":"Blood"},{"key":"658_CR26","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/(SICI)1097-0215(19991029)83:3<291::AID-IJC1>3.0.CO;2-P","volume":"83","author":"MS Pombo De Oliveira","year":"1999","unstructured":"Pombo De Oliveira MS, Loureiro P, Bittencourt A, et al. Geographic diversity of adult t-cell leukemia\/lymphoma in Brazil. Int J Cancer. 1999;83:291\u20138.","journal-title":"Int J Cancer"},{"key":"658_CR27","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1093\/annonc\/mdn696","volume":"20","author":"J Suzumiya","year":"2009","unstructured":"Suzumiya J, Ohshima K, Tamura K, et al. The international prognostic index predicts outcome in aggressive adult T-cell leukemia\/lymphoma: analysis of 126 patients from the international peripheral T-cell lymphoma project. Ann Oncol. 2009;20:715\u201321.","journal-title":"Ann Oncol"},{"issue":"suppl 1","key":"658_CR28","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1097\/00042560-199600001-00005","volume":"13","author":"B Hanchard","year":"1996","unstructured":"Hanchard B. Adult T-cell leukemia\/lymphoma in Jamaica: 1986\u20131995. J Acquir Immun Defic Syndr Hum Retrovirol. 1996;13(suppl 1):S20\u20135.","journal-title":"J Acquir Immun Defic Syndr Hum Retrovirol"},{"key":"658_CR29","doi-asserted-by":"publisher","first-page":"4177","DOI":"10.1200\/JCO.2010.28.0669","volume":"28","author":"A Bazarbachi","year":"2010","unstructured":"Bazarbachi A, Plumelle Y, Carlos RJ, et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia\/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol. 2010;28:4177\u201383.","journal-title":"J Clin Oncol"},{"key":"658_CR30","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/978-1-62703-170-7_8","volume-title":"T-cell lymphomas","author":"K Tsukasaki","year":"2013","unstructured":"Tsukasaki K, Tobinai K. HTLV-1-associated T-cell diseases. In: Francine F, editor. T-cell lymphomas. New York: Humana; 2013. p. 113\u201335."},{"key":"658_CR31","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1182\/blood.V124.21.1685.1685","volume":"124","author":"MI Zell","year":"2014","unstructured":"Zell MI, Assal A, Konda B, et al. Analysis of large cohort shows that Caribbean adult T cell leukemia\/lymphoma is a chemotherapy refractory disease with very poor prognosis that behaves distinctly from Japanese subtypes. Blood. 2014;124:1685.","journal-title":"Blood"},{"key":"658_CR32","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma","year":"1993","unstructured":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma. The international non-Hodgkin\u2019s lymphoma prognostic factors project. N Engl J Med. 1993;329:987\u201394.","journal-title":"N Engl J Med"},{"key":"658_CR33","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/bjh.12962","volume":"166","author":"T Fukushima","year":"2014","unstructured":"Fukushima T, Nomura S, Shimoyama M, et al. Japan Clinical Oncology Group (JCOG) prognostic index and characterization of long-term survivors of aggressive adult T-cell leukaemia-lymphoma (JCOG0902A). Br J Haematol. 2014;166:739\u201348.","journal-title":"Br J Haematol"},{"key":"658_CR34","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): non-Hodgkin\u2019s lymphomas. Version 2.2015, 2015."},{"key":"658_CR35","doi-asserted-by":"publisher","first-page":"e408","DOI":"10.1038\/bcj.2016.21","volume":"6","author":"L Ratner","year":"2016","unstructured":"Ratner L, Rauch D, Abel H, et al. Dose-adjusted EPOCH chemotherapy with bortezomib and raltegravir for human T-cell leukemia virus-associated adult T-cell leukemia lymphoma. Blood Cancer J. 2016;6:e408.","journal-title":"Blood Cancer J"},{"key":"658_CR36","doi-asserted-by":"publisher","first-page":"e4420","DOI":"10.1371\/journal.pone.0004420","volume":"4","author":"L Ratner","year":"2009","unstructured":"Ratner L, Harrington W, Feng X, et al. Human T cell leukemia virus reactivation with progression of adult T-cell leukemia\u2013lymphoma. PLoS One. 2009;4:e4420.","journal-title":"PLoS One"},{"key":"658_CR37","unstructured":"British Committee for Standards in Haematology. Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma). http:\/\/www.guideline.gov\/content.aspx?id=47071 . Accessed October 30, 2017."},{"key":"658_CR38","doi-asserted-by":"publisher","first-page":"4337","DOI":"10.1182\/blood-2009-09-242347","volume":"115","author":"Y Takasaki","year":"2010","unstructured":"Takasaki Y, Iwanaga M, Imaizumi Y, et al. Long-term study of indolent adult T-cell leukemia\u2013lymphoma. Blood. 2010;115:4337\u201343.","journal-title":"Blood"},{"key":"658_CR39","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1200\/JCO.2007.11.9958","volume":"25","author":"K Tsukasaki","year":"2007","unstructured":"Tsukasaki K, Utsunomiya A, Fukuda H, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia\u2013lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007;25:5458\u201364.","journal-title":"J Clin Oncol"},{"key":"658_CR40","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/sj.bmt.1701533","volume":"23","author":"K Tsukasaki","year":"1999","unstructured":"Tsukasaki K, Maeda T, Arimura K, et al. Poor outcome of autologous stem cell transplantation for adult T cell leukemia\/lymphoma: a case report and review of the literature. Bone Marrow Transplant. 1999;23:87\u20139.","journal-title":"Bone Marrow Transplant"},{"key":"658_CR41","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1038\/bmt.2016.154","volume":"51","author":"EH Phillips","year":"2016","unstructured":"Phillips EH, Hodson A, Hermine O, Bazarbachi A, Cwynarski K. Striving to cure adult T-cell leukaemia\/lymphoma: a role for allogeneic stem cell transplant? Bone Marrow Transplant. 2016;51:1549\u201355.","journal-title":"Bone Marrow Transplant"},{"key":"658_CR42","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1182\/blood-2009-10-247510","volume":"116","author":"M Hishizawa","year":"2010","unstructured":"Hishizawa M, Kanda J, Utsunomiya A, et al. Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood. 2010;116:1369\u201376.","journal-title":"Blood"},{"key":"658_CR43","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1182\/blood-2012-03-414490","volume":"120","author":"T Ishida","year":"2012","unstructured":"Ishida T, Hishizawa M, Kato K, et al. Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia\u2013lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study. Blood. 2012;120:1734\u201341.","journal-title":"Blood"},{"key":"658_CR44","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1007\/BF02986621","volume":"77","author":"K Tobinai","year":"2003","unstructured":"Tobinai K, Uike N, Saburi Y, et al. Phase II study of cladribine (2-chlorodeoxyadenosine) in relapsed or refractory adult T-cell leukemia\u2013lymphoma. Int J Hematol. 2003;77:512\u20137.","journal-title":"Int J Hematol"},{"key":"658_CR45","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/sj.thj.6200374","volume":"5","author":"O Hermine","year":"2004","unstructured":"Hermine O, Dombret H, Poupon J, et al. Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed\/refractory adult T-cell leukemia\/lymphoma. Hematol J. 2004;5:130\u20134.","journal-title":"Hematol J"},{"key":"658_CR46","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1200\/JCO.2009.25.3575","volume":"28","author":"K Yamamoto","year":"2010","unstructured":"Yamamoto K, Utsunomiya A, Tobinai K, et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia\u2013lymphoma and peripheral T-cell lymphoma. J Clin Oncol. 2010;28:1591\u20138.","journal-title":"J Clin Oncol"},{"key":"658_CR47","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","volume":"30","author":"T Ishida","year":"2012","unstructured":"Ishida T, Joh T, Uike N, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia\u2013lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30:837\u201342.","journal-title":"J Clin Oncol"},{"key":"658_CR48","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.1182\/blood.V128.22.4159.4159","volume":"128","author":"A Phillips","year":"2016","unstructured":"Phillips A, Fields P, Hermine O, et al. A prospective, multicenter, randomized study of anti-CCR4 monoclonal antibody mogamulizumab versus investigator\u2019s choice in the treatment of patients with relapsed\/refractory adult T-cell leukemia\u2013lymphoma: overall response rate, progression-free survival, and overall survival. Blood. 2016;128:4159 (abstract).","journal-title":"Blood"},{"key":"658_CR49","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.clim.2014.09.012","volume":"155","author":"JL Berkowitz","year":"2014","unstructured":"Berkowitz JL, Janik JE, Stewart DM, et al. Safety, efficacy, and pharmacokinetics\/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia\/lymphoma. Clin Immunol. 2014;155:176\u201387.","journal-title":"Clin Immunol"},{"key":"658_CR50","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1158\/1078-0432.CCR-16-1022","volume":"23","author":"K Sharma","year":"2017","unstructured":"Sharma K, Janik J, O\u2019Mahony D, et al. Phase II study of alemtuzumab (CAMPATH-1\u00ae) in patients with HTLV-1-associated adult T-cell leukemia\/lymphoma. Clin Cancer Res. 2017;23:35\u201342.","journal-title":"Clin Cancer Res"},{"key":"658_CR51","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1111\/cas.12735","volume":"106","author":"K Ishitsuka","year":"2015","unstructured":"Ishitsuka K, Utsunomiya A, Katsuya H, et al. A phase II study of bortezomib in patients with relapsed or refractory aggressive adult T-cell leukemia\/lymphoma. Cancer Sci. 2015;106:1219\u201323.","journal-title":"Cancer Sci"},{"key":"658_CR52","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1200\/JCO.2014.60.6327","volume":"33","author":"PM Barr","year":"2015","unstructured":"Barr PM, Li H, Spier C, et al. Phase II intergroup trial of alisertib in relapsed and refractory peripheral T-cell lymphoma and transformed mycosis fungoides: SWOG 1108. J Clin Oncol. 2015;33:2399\u2013404.","journal-title":"J Clin Oncol"},{"key":"658_CR53","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1200\/JCO.2016.67.7732","volume":"34","author":"T Ishida","year":"2016","unstructured":"Ishida T, Fujiwara H, Nosaka K, et al. Multicenter phase II study of lenalidomide in relapsed or recurrent adult T-cell leukemia\/lymphoma: ATLL-002. J Clin Oncol. 2016;34:1219\u201323.","journal-title":"J Clin Oncol"},{"key":"658_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.23937\/2469-5696\/1410010","volume":"2","author":"AA Phillips","year":"2015","unstructured":"Phillips AA, Giddings J, Lee SM, Horwitz SM. Lenalidomide in patients with relapsed or refractory HTLV-1 related adult T cell leukemia\/lymphoma (ATLL). Int J Blood Res Disorders. 2015;2:1\u20133.","journal-title":"Int J Blood Res Disorders"},{"key":"658_CR55","doi-asserted-by":"publisher","first-page":"e107","DOI":"10.1016\/S2352-3026(15)00284-7","volume":"3","author":"M Ogura","year":"2016","unstructured":"Ogura M, Imaizumi Y, Uike N, et al. Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study. Lancet Haematol. 2016;3:e107\u201318.","journal-title":"Lancet Haematol"},{"key":"658_CR56","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/bjh.13302","volume":"169","author":"Y Suehiro","year":"2015","unstructured":"Suehiro Y, Hasegawa A, Iino T, et al. Clinical outcomes of a novel therapeutic vaccine with Tax peptide-pulsed dendritic cells for adult T cell leukaemia\/lymphoma in a pilot study. Br J Haematol. 2015;169:356\u201367.","journal-title":"Br J Haematol"},{"key":"658_CR57","unstructured":"Theravectys. Theravectys obtains orphan drug designation from the European Medicines Agency for its lentiviral vector-based therapeutic vaccine against adult T-cell leukemia and lymphoma [press release]. http:\/\/www.theravectys.com\/wp-content\/uploads\/PDF\/14_Theravectys_obtains_Orphan_Drug_Designation_from_EMA.pdf . Accessed October 30, 2017."},{"key":"658_CR58","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1158\/1078-0432.CCR-15-1412","volume":"22","author":"RJ Kreitman","year":"2016","unstructured":"Kreitman RJ, Stetler-Stevenson M, Jaffe ES, et al. Complete remissions of adult T-cell leukemia with anti-CD25 recombinant immunotoxin LMB-2 and chemotherapy to block immunogenicity. Clin Cancer Res. 2016;22:310\u20138.","journal-title":"Clin Cancer Res"},{"key":"658_CR59","unstructured":"Leustatin\u00ae (cladribine) injection [prescribing information]. Raritan, NJ: Centocor Ortho Biotech Products, L.P.; July, 2012."},{"key":"658_CR60","unstructured":"Litak\u00ae 2\u00a0mg\/ml solution for injection [summary of product characteristics]. Weil\/Rhein, Germany: Lipomed GmbH; August, 2013."},{"key":"658_CR61","unstructured":"Clolar\u00ae (clofarabine) injection, for intravenous use [prescribing information]. Cambridge, MA: Genzyme Corporation; October, 2016."},{"key":"658_CR62","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s11912-005-0003-3","volume":"7","author":"SJ Corey","year":"2005","unstructured":"Corey SJ. New agents in the treatment of childhood leukemias and myelodysplastic syndromes. Curr Oncol Rep. 2005;7:399\u2013405.","journal-title":"Curr Oncol Rep"},{"key":"658_CR63","unstructured":"Evoltra\u00ae 1\u00a0mg\/ml concentrate for solution for infusion [summary of product characteristics]. The Netherlands: Genzyme Europe B.V. October, 2016."},{"key":"658_CR64","unstructured":"Folotyn\u00ae (pralatrexate injection) [prescribing information]. Westminster, CO: Allos Therapeutics, Inc.; May, 2012."},{"key":"658_CR65","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","volume":"29","author":"OA O\u2019Connor","year":"2011","unstructured":"O\u2019Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29:1182\u20139.","journal-title":"J Clin Oncol"},{"key":"658_CR66","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.2165\/11631090-000000000-00000","volume":"72","author":"JM Subramaniam","year":"2012","unstructured":"Subramaniam JM, Whiteside G, McKeage K, Croxtall JC. Mogamulizumab: first global approval. Drugs. 2012;72:1293\u20138.","journal-title":"Drugs"},{"key":"658_CR67","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1111\/j.1349-7006.2006.00307.x","volume":"97","author":"T Ishida","year":"2006","unstructured":"Ishida T, Ueda R. CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Sci. 2006;97:1139\u201346.","journal-title":"Cancer Sci"},{"key":"658_CR68","unstructured":"Approval for additional indication for PTCL and CTCL of mogamulizumab. http:\/\/www.kyowa-kirin.com\/news_releases\/2014\/e20140317_01.html . Accessed October 30, 2017."},{"key":"658_CR69","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/bjh.13338","volume":"169","author":"T Ishida","year":"2015","unstructured":"Ishida T, Jo T, Takemoto S, et al. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study. Br J Haematol. 2015;169:672\u201382.","journal-title":"Br J Haematol"},{"key":"658_CR70","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-09-2697","volume":"16","author":"T Ishii","year":"2010","unstructured":"Ishii T, Ishida T, Utsunomiya A, et al. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia\/lymphoma. Clin Cancer Res. 2010;16:1520\u201331.","journal-title":"Clin Cancer Res"},{"key":"658_CR71","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1074\/jbc.M210665200","volume":"278","author":"T Shinkawa","year":"2003","unstructured":"Shinkawa T, Nakamura K, Yamane N, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem. 2003;278:3466\u201373.","journal-title":"J Biol Chem"},{"key":"658_CR72","doi-asserted-by":"publisher","first-page":"17945","DOI":"10.1073\/pnas.1316796110","volume":"110","author":"D Sugiyama","year":"2013","unstructured":"Sugiyama D, Nishikawa H, Maeda Y, et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci USA. 2013;110:17945\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"key":"658_CR73","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1158\/1078-0432.CCR-14-0830","volume":"21","author":"X Ni","year":"2015","unstructured":"Ni X, Jorgensen JL, Goswami M, et al. Reduction of regulatory T cells by mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive\/refractory mycosis fungoides and S\u00e9zary syndrome. Clin Cancer Res. 2015;21:274\u201385.","journal-title":"Clin Cancer Res"},{"key":"658_CR74","doi-asserted-by":"publisher","first-page":"4327","DOI":"10.1158\/1078-0432.CCR-15-0357","volume":"21","author":"K Kurose","year":"2015","unstructured":"Kurose K, Ohue Y, Wada H, et al. Phase Ia study of FoxP3\u00a0+\u00a0CD4 treg depletion by infusion of a humanized anti-CCR4 antibody, KW-0761, in cancer patients. Clin Cancer Res. 2015;21:4327\u201336.","journal-title":"Clin Cancer Res"},{"key":"658_CR75","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1200\/JCO.2016.67.8250","volume":"34","author":"S Fuji","year":"2016","unstructured":"Fuji S, Inoue Y, Utsunomiya A, et al. Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-cell leukemia\/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality. J Clin Oncol. 2016;34:3426\u201333.","journal-title":"J Clin Oncol"},{"key":"658_CR76","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/j.bbmt.2016.05.017","volume":"22","author":"T Sugio","year":"2016","unstructured":"Sugio T, Kato K, Aoki T, et al. Mogamulizumab treatment prior to allogeneic hematopoietic stem cell transplantation induces severe acute graft-versus-host disease. Biol Blood Marrow Transplant. 2016;22:1608\u201314.","journal-title":"Biol Blood Marrow Transplant"},{"key":"658_CR77","unstructured":"Adcetris\u00ae (brentuximab vedotin) [prescribing information]. Bothell, WA: Seattle Genetics, Inc.; November, 2017."},{"key":"658_CR78","unstructured":"Adcetris\u00ae 50\u00a0mg powder for concentrate for solution for infusion [summary of product characteristics]. Taastrup, Denmark: Takeda Pharma A\/S; May, 2015."},{"key":"658_CR79","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1200\/JCO.2013.54.2456","volume":"32","author":"MA Fanale","year":"2014","unstructured":"Fanale MA, Horwitz SM, Forero-Torres A, et al. Brentuximab vedotin in the front-line treatment of patients with CD30+\u00a0peripheral T-cell lymphomas: results of a phase I study. J Clin Oncol. 2014;32:3137\u201343.","journal-title":"J Clin Oncol"},{"key":"658_CR80","unstructured":"Campath\u00ae (alemtuzumab) [prescribing information]. Cambridge, MA: Genzyme Corporation; September, 2014."},{"key":"658_CR81","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1586\/14737140.5.1.39","volume":"5","author":"F Ravandi","year":"2005","unstructured":"Ravandi F, O\u2019Brien S. Alemtuzumab. Expert Rev Anticancer Ther. 2005;5:39\u201351.","journal-title":"Expert Rev Anticancer Ther"},{"key":"658_CR82","unstructured":"Velcade\u00ae (bortezomib) for injection [prescribing information]. Cambridge, MA: Millennium Pharmaceuticals, Inc.; June, 2008."},{"key":"658_CR83","unstructured":"Velcade\u00ae 1\u00a0mg powder for solution for injection [summary of product characteristics]. Beerse, Belgium: Janssen-Cilag International NV; March, 2015."},{"key":"658_CR84","unstructured":"Revlimid\u00ae (lenalidomide) [prescribing information]. Summit, NJ: Celgene Corporation; 2007."},{"key":"658_CR85","unstructured":"Revlimid\u00ae 2.5\u00a0mg hard capsules [summary of product characteristics]. Uxbridge, United Kingdom: Celgene Europe Limited; March, 2015."},{"key":"658_CR86","doi-asserted-by":"crossref","unstructured":"Revaud D, Bejanariu A, Loussaief L, et al. Development of an anti-HTLV-1 vaccine for the treatment of adult T-cell leukemia\/lymphoma. Presented at: 57th Annual Meeting and Exposition of the American Society of Hematology, December 5\u20138, 2015, Orlando, FL.","DOI":"10.1182\/blood.V126.23.4010.4010"},{"key":"658_CR87","doi-asserted-by":"publisher","first-page":"6528","DOI":"10.1182\/blood-2009-03-211821","volume":"113","author":"G Kchour","year":"2009","unstructured":"Kchour G, Tarhini M, Kooshyar MM, et al. Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia\/lymphoma (ATL). Blood. 2009;113:6528\u201332.","journal-title":"Blood"},{"key":"658_CR88","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/1742-4690-10-91","volume":"10","author":"G Kchour","year":"2013","unstructured":"Kchour G, Rezaee R, Farid R, et al. The combination of arsenic, interferon-alpha, and zidovudine restores an \u201cimmunocompetent-like\u201d cytokine expression profile in patients with adult T-cell leukemia lymphoma. Retrovirology. 2013;10:91.","journal-title":"Retrovirology"},{"key":"658_CR89","doi-asserted-by":"publisher","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","volume":"28","author":"SJ Whittaker","year":"2010","unstructured":"Whittaker SJ, Demierre MF, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010;28:4485\u201391.","journal-title":"J Clin Oncol"},{"key":"658_CR90","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","volume":"25","author":"EA Olsen","year":"2007","unstructured":"Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25:3109\u201315.","journal-title":"J Clin Oncol"},{"key":"658_CR91","unstructured":"Istodax\u00ae (romidepsin) for injection, for intravenous use [prescribing information]. Summit, NJ: Celgene Corporation; July, 2016."},{"key":"658_CR92","unstructured":"Zolinza\u00ae (vorinostat) capsules [prescribing information]. Whitehouse Station, NJ: Merck & Co., Inc.; December, 2015."},{"issue":"suppl 1","key":"658_CR93","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1742-4690-8-S1-A48","volume":"8","author":"JC Ramos","year":"2011","unstructured":"Ramos JC, Toomey N, Diaz L, Ruiz P, Barber G, Harrington W Jr. Targeting HTLV-I latency in adult T-cell leukemia\/lymphoma [abstract]. Retrovirology. 2011;8(suppl 1):16 (Abstract A48).","journal-title":"Retrovirology"},{"key":"658_CR94","unstructured":"Toomey N, Ramos JC. The combination of belinostat with zidovudine for treatment of HTLV-I related adult T-cell leukemia\u2013lymphoma. Presented at: 57th American Society of Hematology Annual Meeting and Exposition, December 5\u20138, 2015, Orlando, FL."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-018-0658-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-018-0658-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-018-0658-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T23:43:21Z","timestamp":1660434201000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-018-0658-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":94,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["658"],"URL":"https:\/\/doi.org\/10.1007\/s12325-018-0658-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"1 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2018","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}